Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 1
1994 2
1995 3
1996 1
1997 1
1998 3
1999 3
2000 2
2001 4
2002 5
2003 12
2004 4
2005 7
2006 8
2007 8
2008 7
2009 6
2010 11
2011 5
2012 6
2013 3
2014 4
2015 3
2016 5
2017 6
2018 1
2020 1
2021 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study.
Yoshino K, Okamoto I, Sato H, Okada T, Tokashiki K, Kondo T, Tsukahara K. Yoshino K, et al. Anticancer Res. 2021 Dec;41(12):6279-6285. doi: 10.21873/anticanres.15449. Anticancer Res. 2021. PMID: 34848484
BACKGROUND/AIM: This study evaluated the utility of the histamine H2-receptor antagonist lafutidine in patients taking oral fluorouracil (S-1) for head and neck squamous cell carcinoma (HNSCC), by comparing patients with and without concomitant lafutidine. ...The pr …
BACKGROUND/AIM: This study evaluated the utility of the histamine H2-receptor antagonist lafutidine in patients taking oral fluoroura …
Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
Sano T, Utsumi D, Amagase K, Matsumoto K, Tominaga M, Higuchi K, Takeuchi T, Kato S. Sano T, et al. J Physiol Pharmacol. 2017 Feb;68(1):79-90. J Physiol Pharmacol. 2017. PMID: 28456772 Free article.
The preventive effects of lafutidine were completely abolished in sensory deafferented and TRPV1-KO mice. ...Lafutidine induced Alcian Blue and PAS-positive mucus production in the small intestine. ...
The preventive effects of lafutidine were completely abolished in sensory deafferented and TRPV1-KO mice. ...Lafutidine induce …
Lafutidine-induced increase in intracellular ca(2+) concentrations in PC12 and endothelial cells.
Kunieda K, Someya A, Horie S, Ajioka H, Murayama T. Kunieda K, et al. J Pharmacol Sci. 2005 Jan;97(1):67-74. doi: 10.1254/jphs.fpj04042x. Epub 2005 Jan 15. J Pharmacol Sci. 2005. PMID: 15655292 Free article.
Since the effect of lafutidine on the intracellular Ca(2+) concentration ([Ca(2+)](i)) in cells has not been elucidated, we investigated the lafutidine response to [Ca(2+)](i) in rat pheochromocytoma PC12 and human endothelial cells. ...In endothelial cells, lafu …
Since the effect of lafutidine on the intracellular Ca(2+) concentration ([Ca(2+)](i)) in cells has not been elucidated, we investiga …
[Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity].
Tanaka M, Banba M, Joko A, Moriyama Y. Tanaka M, et al. Nihon Yakurigaku Zasshi. 2001 Jun;117(6):377-86. doi: 10.1254/fpj.117.377. Nihon Yakurigaku Zasshi. 2001. PMID: 11436515 Review. Japanese.
Lafutidine exhibited potent and long-lasting H2 antagonism and prolonged antisecretion. ...Furthermore, effectiveness of lafutidine against NSAIDs-induced ulcer was high. From these results, lafutidine is equal or superior to conventional H2 antagonists in an …
Lafutidine exhibited potent and long-lasting H2 antagonism and prolonged antisecretion. ...Furthermore, effectiveness of lafutidin …
Lafutidine Ameliorates Indomethacin-Induced Small Intestinal Damage in Rats by Modifying the Intestinal Mucosal Barrier, Inflammation, and Microbiota.
Zhu L, Guo J, Liu Q, Luo Y, Zhao J, Zhong W, Sun S, Xu X, Liang H, Lou C, Song C, Chen J, Zhao J, Wang B, Chen X. Zhu L, et al. Pharmacology. 2023;108(3):286-300. doi: 10.1159/000529879. Epub 2023 Apr 6. Pharmacology. 2023. PMID: 37023725
INTRODUCTION: Nonsteroidal anti-inflammatory drug (NSAID)-induced small intestinal damage is a serious and escalating clinical problem without effective treatment. Lafutidine (LAF) is a novel histamine H2 receptor antagonist with a mucosal protective action. ...
INTRODUCTION: Nonsteroidal anti-inflammatory drug (NSAID)-induced small intestinal damage is a serious and escalating clinical problem witho …
Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: a randomized, double-blinded, placebo controlled study.
Kato M, Kamada G, Yamamoto K, Nishida U, Imai A, Yoshida T, Ono S, Nakagawa M, Nakagawa S, Shimizu Y, Asaka M. Kato M, et al. J Gastroenterol Hepatol. 2010 Oct;25(10):1631-5. doi: 10.1111/j.1440-1746.2010.06375.x. J Gastroenterol Hepatol. 2010. PMID: 20880171 Clinical Trial.
Both groups received 81 mg of aspirin once daily for 14 days (on days 1 to 14) and 60 mg of loxoprofen three times daily for the last 7 days (on days 8 to 14). Placebo or 10 mg of lafutidine was administered twice daily for 14 days in each group. After a 2-week washout per …
Both groups received 81 mg of aspirin once daily for 14 days (on days 1 to 14) and 60 mg of loxoprofen three times daily for the last 7 days …
Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress.
Sato H, Kawashima K, Yuki M, Kazumori H, Rumi MA, Ortega-Cava CF, Ishihara S, Kinoshita Y. Sato H, et al. J Lab Clin Med. 2003 Feb;141(2):102-5. doi: 10.1067/mlc.2003.12. J Lab Clin Med. 2003. PMID: 12577045
Lafutidine pretreatment before WRS caused a significant increase in serum CGRP concentration compared with famotidine (lafutidine, 86.64 +/- 9.52 pg/mL; famotidine, 47.55 +/- 4.35 pg/mL; control, 58.43 +/- 6.07 pg/mL). Our results suggest that lafutidine augm …
Lafutidine pretreatment before WRS caused a significant increase in serum CGRP concentration compared with famotidine (lafutidine …
A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
Cho K, Saikawa H, Hashimoto T, Katagiri H, Owada Y, Yakuwa K, Fujimura I, Utsumi Y, Akiyama M, Nagashima H, Takahashi F, Maemondo M. Cho K, et al. Ann Palliat Med. 2023 Nov;12(6):1136-1145. doi: 10.21037/apm-23-90. Epub 2023 Sep 18. Ann Palliat Med. 2023. PMID: 37731302 Free article. Clinical Trial.
The aim of this study was to assess the preventive effect of lafutidine on CIPN. METHODS: Patients were randomly assigned (1:1) to carboplatin and paclitaxel chemotherapy with lafutidine 10 mg twice daily (lafutidine group) or without lafutidine (contr …
The aim of this study was to assess the preventive effect of lafutidine on CIPN. METHODS: Patients were randomly assigned (1:1) to ca …
Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial.
Kim EH, Lee YC, Chang YW, Park JJ, Chun HJ, Jung HY, Kim HS, Jeong HY, Seol SY, Han SW, Choi MG, Park SH, Lee OJ, Jung JT, Lee DH, Jung HC, Lee ST, Kim JG, Youn SJ, Kim HY, Lee SW. Kim EH, et al. Dig Dis Sci. 2015 Jun;60(6):1724-32. doi: 10.1007/s10620-014-3489-4. Epub 2014 Dec 23. Dig Dis Sci. 2015. PMID: 25532503 Clinical Trial.
CONCLUSIONS: Lafutidine was non-inferior to famotidine in healing of reflux esophagitis. Lafutidine, however, was superior to famotidine in terms of symptom relief of reflux esophagitis....
CONCLUSIONS: Lafutidine was non-inferior to famotidine in healing of reflux esophagitis. Lafutidine, however, was superior to …
Palliative effect of lafutidine on oral burning sensation.
Toida M, Kato K, Makita H, Long NK, Takeda T, Hatakeyama D, Yamashita T, Shibata T. Toida M, et al. J Oral Pathol Med. 2009 Mar;38(3):262-8. doi: 10.1111/j.1600-0714.2008.00736.x. Epub 2009 Jan 23. J Oral Pathol Med. 2009. PMID: 19175712 Clinical Trial.
This effect may make lafutidine useful for the treatment of burning mouth syndrome (BMS). ...Only two mild abdominal adverse events occurred in the lafutidine group, but neither required the termination of treatment. ...
This effect may make lafutidine useful for the treatment of burning mouth syndrome (BMS). ...Only two mild abdominal adverse events o …
122 results